Howard L Kaufman
Overview
Explore the profile of Howard L Kaufman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
11192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azad A, Zhang J, Emerick K, Shalhout S, Kaufman H, Miller D, et al.
Ophthalmic Plast Reconstr Surg
. 2025 Mar;
PMID: 40081357
Purpose: To review the treatment response of advanced conjunctival squamous cell carcinoma (SCC) to systemic immune checkpoint inhibitor (ICI) therapy at a single institution. Methods: A retrospective review of patients...
2.
Mistry H, Hodson D, Battula S, Schmidt M, Tighe R, Kaufman H, et al.
Mol Cancer Ther
. 2025 Mar;
PMID: 40079372
Interleukin-12 (IL-12) mediates innate and adaptive immune responses and has demonstrated therapeutic anti-tumor activity but clinical development has been hindered by a narrow therapeutic window. We generated a novel IL-12...
3.
4.
Ayele K, Wakimoto H, Nauwynck H, Kaufman H, Rabkin S, Saha D
Mol Ther
. 2025 Jan;
PMID: 39741405
Oncolytic herpes simplex viruses (oHSV) preferentially replicate in cancer cells while inducing antitumor immunity, and thus, they are often referred to as in situ cancer vaccines. OHSV infection of tumors...
5.
Sierra-Davidson K, Dedeilia A, Lawless A, Sharova T, Kaufman H, Boland G, et al.
Ann Surg Oncol
. 2024 Dec;
32(4):2773-2774.
PMID: 39653945
No abstract available.
6.
Passos Barbosa M, Kamerer R, Schmit J, Lopez A, Uyehara R, Tighe R, et al.
Mol Cancer Ther
. 2024 Dec;
24(3):406-418.
PMID: 39632727
Melanoma is an aggressive cancer in dogs involving skin and mucosa similar to humans. Anchored immunotherapeutics offer a novel approach to increase intratumoral retention of therapeutic payloads while decreasing systemic...
7.
Sierra-Davidson K, Dedeilia A, Lawless A, Sharova T, Kaufman H, Boland G, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):482-494.
PMID: 39422848
Background: Talimogene laherparapvec (T-VEC) is a modified herpes simplex virus type 1 (HSV-1) and the first oncolytic virus to be approved for the treatment of unresectable melanoma. We assessed whether...
8.
Mooradian M, Fintelmann F, LaSalle T, Simon J, Graur A, Muzikansky A, et al.
Nat Commun
. 2024 Aug;
15(1):7357.
PMID: 39191779
Image-guided percutaneous cryoablation is an established minimally invasive oncologic treatment. We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumor response...
9.
Wang H, Borlongan M, Kaufman H, Le U, Nauwynck H, Rabkin S, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38821716
Cytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity...
10.
Miller D, Shalhout S, Wright K, Miller M, Kaufman H, Emerick K, et al.
Cancer
. 2024 May;
130(15):2670-2682.
PMID: 38696121
Background: Merkel cell carcinoma (MCC) is an aggressive cancer with often poor outcomes. Limited biomarkers exist for predicting clinical outcomes. The Merkel cell polyomavirus (MCPyV) serum antibody test (AMERK) has...